While downregulation of SRCIN1, DAB2IP, and SRC expression in tumor-like cells and tumor spheres indicates a loss of regulatory signaling, possibly contributing to malignancy, SLA might compensate these regulators, and the upregulation of matrix metalloproteinases MMP13 and ADAM15, known to contribute to glioma/glioblastoma aggressiveness,85,86 supports the invasive potential of these cells. The gene discussed is SRCIN1; the disease is glioblastoma.